DXCM
DexCom, Inc.
DXCM has the edge over UNH overall, supported by stronger fundamentals and stronger valuation.
UNH
UnitedHealth Group Incorporated
UNH's outlook is improving, though it still trails on the overall score.
DXCM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
DXCM's revenue, profitability, cash flow and balance sheet are all currently healthy.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
DXCM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 28x | $81.39 | — |
| Current | 32x | $81.39 | — |
| Cheap | 42x | $107 | +31% |
| Fair | 97x | $248 | +204% |
| Expensive | 192x | $487 | +498% |
Historical ranges are pointers, not guarantees.
DXCM has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
DXCM Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
DXCM has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
DXCM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.94 | +16% |
| Q3 2026 | $2.54 | +42% |
| Q2 2026 | $2.52 | +76% |
| Q1 2026 | $2.33 | +75% |
| Q4 2025 | $2.09 | +47% |
| Q3 2025 | $1.79 | +7.8% |
| Q2 2025 | $1.43 | -11% |
| Q1 2025 | $1.33 | -14% |
| Q4 2024 | $1.42 | +9.2% |
DXCM has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
DXCM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +11% |
| Q2 2026 | $1.3B | +13% |
| Q1 2026 | $1.2B | +15% |
| Q4 2025 | $1.3B | +13% |
| Q3 2025 | $1.2B | +22% |
| Q2 2025 | $1.2B | +15% |
| Q1 2025 | $1B | +12% |
| Q4 2024 | $1.1B | +7.6% |
DXCM has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +4.3 points |
| Q2 2026 | 24% | +6 points |
| Q1 2026 | 21% | +8.5 points |
| Q4 2025 | 26% | +8.7 points |
| Q3 2025 | 20% | +4.8 points |
| Q2 2025 | 18% | +2.6 points |
| Q1 2025 | 13% | +1.9 points |
| Q4 2024 | 17% | -4 points |
DXCM has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
DXCM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $272.7M | -53% |
| Q2 2026 | $184.5M | -12% |
| Q1 2026 | $449M | +364% |
| Q4 2025 | $192.1M | +8.7% |
| Q3 2025 | $579.4M | +556% |
| Q2 2025 | $208.9M | -2.1% |
| Q1 2025 | $96.8M | -36% |
| Q4 2024 | $176.8M | +118% |
DXCM generated $1.1B in free cash flow over the past year, up 3.4% from the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over DXCM on cash flow, with more consistent year-over-year improvement.
DXCM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -6.6M shares |
| 1 year | -5.9% | -23.9M shares |
| 3 years | -10% | -43.3M shares |
| 5 years | -4.6% | -18.5M shares |
| Available history | +3.9% | +14.3M shares |
DXCM has the edge over UNH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $400M |
| Q4 2025 | $312.8M |
| Q4 2024 | — |
| Q3 2024 | $750M |
| Q4 2023 | $500M |
| Q3 2023 | — |
| Q4 2022 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
DXCM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.2x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | 0.3x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 1.8x | Healthy |
| Q4 2024 | 2.2x | Moderate |
DXCM has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
DXCM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.7 | Neutral |
| Stochastic | 32.8 | Neutral |
DXCM's weekly RSI is 52 (neutral) and its Stochastic is 33 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
DXCM PE vs Healthcare Sector
| Metric | DXCM | Sector median | Relative |
|---|---|---|---|
| PE | 32x | 26x | 24% above |
| PE % | 6 | 29 | 23 pts below |
DXCM is trading at 32x earnings, a 24% premium to the Healthcare sector's median of 26x.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over DXCM on valuation relative to its sector.
DXCM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $82.9 | 1.8% below |
| 20 week MA | $83.0 | 1.9% below |
| 50 week MA | $73.9 | 10% above |
| 100 week MA | $75.3 | 8.1% above |
| 200 week MA | $91.3 | 11% below |
DXCM's trend is mixed: it's above two of its five weekly moving averages, and 11% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over DXCM on trend strength, trading above more of its moving averages.
DXCM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.5 | $88.8 | +63% |
| 2021 | $88.8 | $143.0 | +61% |
| 2022 | $143.0 | $111.4 | -22% |
| 2023 | $111.4 | $124.1 | +11% |
| 2024 | $124.1 | $80.2 | -35% |
| 2025 | $80.2 | $67.6 | -16% |
| 2026 YTD | $67.6 | $81.4 | +20% |
DXCM has finished lower in three of the last six years. It's up 20% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over DXCM on returns for 2026, with the stronger performance.